ArticleBMC psychiatry2026
Prescribing medications for attention-deficit/hyperactivity disorder in children: a retrospective analysis of a Japanese health insurance claims database.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite pharmacotherapy being a significant treatment protocol for attention-deficit/hyperactivity disorder (ADHD), an increasingly common neurodevelopmental condition among children in Japan, prescribing practices for ADHD medications remain underexplored. This study examined prescribing patterns of medications for ADHD in children and adolescents aged 0-17 years in Japan and analyzed drug selection trends on the basis of patients' backgrounds, including sex, age group, and medical department.
methodsIn this retrospective database study using a large Japanese health insurance claims database, we analyzed prescription patterns from April 2018 to August 2023. We examined the proportion of patients prescribed each of the four ADHD medications, namely, Osmotic controlled-release oral delivery system methylphenidate (OROS-MPH), atomoxetine (ATX), guanfacine (GXR), and lisdexamfetamine (LDX), their combination patterns, and new prescription proportions across different demographic groups and medical departments. The Jonckheere-Terpstra trend test was employed to assess trends in prescription proportions over time. The Mann‒Whitney U test was employed to compare time series data on the proportion of monotherapy prescriptions in psychiatric and nonpsychiatric settings.
resultsFrom 2018 to 2023, OROS-MPH prescriptions significantly decreased from 64.7% to 47.5%, whereas GXR prescriptions significantly increased from 19.3% to 46.4%. GXR was prescribed most frequently for female patients and children aged 6-12 years. For new patients, GXR prescriptions began exceeding those of OROS-MPH from late 2019 onward, comprising 41.3% of new prescriptions by 2023. The percentage of patients receiving monotherapy decreased from 82.3% to 79.6%, with OROS-MPH plus GXR being the most common combination therapy.
conclusionsIn Japan, GXR has become an increasingly preferred medication for ADHD, particularly for female patients and children aged 6-12 years, with new prescriptions exceeding those of OROS-MPH since late 2019. This trend may be attributed to GXR not being subject to the same distribution control regulations as central nervous system stimulants and to its distinctive pharmacological mechanisms that differ from those of other ADHD medications. Continuous monitoring of prescription practices is necessary as treatment options continue to evolve. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.